Acute myeloid leukemia and acute lymphocytic leukemia
Conditions
Interventions
Group 1: Adult patients with newly diagnosed acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) who actively declare their participation in the study and are not eligible for stem cell
Sponsors
Carl von Ossietzky Universität Oldenburg, Fakultät VI, Abt. Pharmakologie & Toxikologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed AML and ALL who have actively consented to the study.
Exclusion criteria
Exclusion criteria: The following patients are excluded: Children, persons who are unable to give consent to the study, pregnant women, patients treated exclusively in palliative care and patients who receive or actively seek a hospice place as well as patients after bone marrow transplantation and under CAR-T cell therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of statistically significant differences in the concentration of bioactive lipid species between leukemia patients and healthy control groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of statistically significant differences in PCR and Western blot analyzes in selected immune cell populations in dependency to lipid-associated proteins. | — |
Countries
Germany
Contacts
Public ContactBernhard Rauch
Carl von Ossietzky Universität Oldenburg, Fakultät VI, Abt. Pharmakologie & Toxikologie
Outcome results
None listed